Last update 22 Mar 2025

Pioglitazone Hydrochloride/Sitagliptin Phosphate Monohydrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Janacti, Pioglitazine/sitagliptin, Sitagliptin/pioglitazone
+ [2]
Target
DPP-4 x PPARγ
Action
inhibitors, agonists
Mechanism
DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), PPARγ agonists(Peroxisome proliferator-activated receptor γ agonists)
Therapeutic Areas
Endocrinology and Metabolic Disease
Active Indication-
Inactive Indication
Diabetes Mellitus, Type 2
Originator Organization
Merck & Co., Inc.Merck & Co., Inc.
Active Organization-
Inactive Organization
Merck GmbHMerck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
Drug Highest PhaseDiscontinuedNDA/BLA
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC19H21ClN2O3S
InChIKeyGHUUBYQTCDQWRA-UHFFFAOYSA-N
CAS Registry112529-15-4
View All Structures (2)

Related

1
Clinical Trials associated with Pioglitazone Hydrochloride/Sitagliptin Phosphate Monohydrate
NCT01006018
/ TerminatedNot ApplicableIIT
DPP-4 Inhibition and Thiazolidinedione for Diabetes Mellitus Prevention (DInT DM Study)
100 Clinical Results associated with Pioglitazone Hydrochloride/Sitagliptin Phosphate Monohydrate
Login to view more data
100 Translational Medicine associated with Pioglitazone Hydrochloride/Sitagliptin Phosphate Monohydrate
Login to view more data
100 Patents (Medical) associated with Pioglitazone Hydrochloride/Sitagliptin Phosphate Monohydrate
Login to view more data
100 Deals associated with Pioglitazone Hydrochloride/Sitagliptin Phosphate Monohydrate
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2NDA/BLA
European Union
Merck GmbH
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT01006018 (DInT DM, CTgov)
Not Applicable
Prediabetic State
3
(Sitagliptin + Pioglitazone PLACEBO)
cbudzezhgw(kmkwsqcxdo) = tifiwaoptl rmnhmdstdk (apoilcnlzg, lmerhyibhs - gfowkypndw)
View more
-
07 Jun 2013
(Sitagliptin + Pioglitazone)
cbudzezhgw(kmkwsqcxdo) = sxfkgpptku rmnhmdstdk (apoilcnlzg, nnohflpfxp - nkrozcznqv)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free